JPWO2018199287A1 - クリスタリン網膜症の処置および／または予防方法 - Google Patents

クリスタリン網膜症の処置および／または予防方法 Download PDF

Info

Publication number
JPWO2018199287A1
JPWO2018199287A1 JP2019514654A JP2019514654A JPWO2018199287A1 JP WO2018199287 A1 JPWO2018199287 A1 JP WO2018199287A1 JP 2019514654 A JP2019514654 A JP 2019514654A JP 2019514654 A JP2019514654 A JP 2019514654A JP WO2018199287 A1 JPWO2018199287 A1 JP WO2018199287A1
Authority
JP
Japan
Prior art keywords
cells
ips
bcd
rpe
rpe cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019514654A
Other languages
English (en)
Japanese (ja)
Inventor
匡侑 畑
匡侑 畑
華子 池田
華子 池田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University
Original Assignee
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University filed Critical Kyoto University
Publication of JPWO2018199287A1 publication Critical patent/JPWO2018199287A1/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019514654A 2017-04-28 2018-04-27 クリスタリン網膜症の処置および／または予防方法 Pending JPWO2018199287A1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2017090296 2017-04-28
JP2017090296 2017-04-28
PCT/JP2018/017183 WO2018199287A1 (fr) 2017-04-28 2018-04-27 Procédé de traitement prophylactique et/ou thérapeutique de la rétinopathie cristalline

Publications (1)

Publication Number Publication Date
JPWO2018199287A1 true JPWO2018199287A1 (ja) 2020-03-12

Family

ID=63919752

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019514654A Pending JPWO2018199287A1 (ja) 2017-04-28 2018-04-27 クリスタリン網膜症の処置および／または予防方法

Country Status (2)

Country Link
JP (1) JPWO2018199287A1 (fr)
WO (1) WO2018199287A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021114662A1 (fr) * 2019-12-09 2021-06-17 北京大学第三医院（北京大学第三临床医学院） Utilisations de cyp4v2 et rdcvf dans la préparation de médicaments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524444A (ja) * 2012-08-03 2015-08-24 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ライソゾーム蓄積症を治療するためのシクロデキストリン

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
EP3078379B1 (fr) * 2013-12-05 2018-11-28 National University Corporation Kumamoto University Médicament pour le traitement de troubles d'accumulation de cholestérol et méthode de sélection de ce dernier

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015524444A (ja) * 2012-08-03 2015-08-24 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ライソゾーム蓄積症を治療するためのシクロデキストリン

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CORNEA, vol. 20, no. 2, JPN6018028213, 2001, pages 183 - 186, ISSN: 0004753349 *
PNAS, vol. 115, no. 15, JPN6018028216, 10 April 2018 (2018-04-10), pages 3936 - 3941, ISSN: 0004753350 *

Also Published As

Publication number Publication date
WO2018199287A1 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
US20120052138A1 (en) Composition comprising green tea extract
JP2013534517A (ja) ラマリンを含有する炎症疾患または免疫疾患の予防または治療用医薬組成物
JP2019503401A (ja) ピロロキノリンキノン、その誘導体及び／又は塩の乾燥症候群における使用ならびに医薬組成物
WO2020252005A1 (fr) Procédés et compositions pour modifier un phénotype sécrétoire associé à la sénescence
WO2018199287A1 (fr) Procédé de traitement prophylactique et/ou thérapeutique de la rétinopathie cristalline
US7482027B2 (en) Composition for the prevention or treatment of diseases associated with angiogenesis
KR20220002151A (ko) 티로신을 유효성분으로 함유하는 단백질 내 티로신의 니트로화에 의한 질환의 예방, 개선 또는 치료용 조성물
WO2020179747A1 (fr) Composition inhibitrice d'hif
US20130225501A1 (en) Skin collagen production-promoting agent
JP6873504B2 (ja) アルツハイマー病の治療及び／又は予防のための組成物
KR20110061194A (ko) 탄닌산 및 퀘르세틴을 유효성분으로 함유하는 아토피성 피부염 예방, 개선 또는 치료용 조성물
KR20150071932A (ko) Taz 단백질 활성화 유도 성분을 포함하는 근육 분화 및 근육재생용 약학적 조성물
JP5897783B2 (ja) 抗アンドロゲン剤及び皮脂分泌抑制剤
JP2004002231A (ja) ルブロフサリン配糖体含有組成物
JP5109113B2 (ja) ＩｇＥ捕捉剤、並びに抗アレルギー性の医薬組成物、化粧料組成物、食料組成物、飲料組成物及び飼料組成物
KR102374440B1 (ko) 후코스테롤을 유효성분으로 함유하는 난소암 예방 또는 치료용 조성물
EP2709643B1 (fr) Compositions comprenant des extraits ou des matières dérivés de liqueur végétale d'huile de palme destinées à l'inhibition de la perte de la vue due à la dégénération maculaire
JP2003267874A (ja) 神経変性疾患の治療薬
KR20170071996A (ko) ＰＤＫｓ 억제제를 유효성분으로 함유하는 알러지성 질환의 예방 또는 치료용 약학적 조성물
JP6792753B2 (ja) フェルラ酸誘導体含有組成物及びその製造方法
KR102625248B1 (ko) 이미다졸린 유도체 화합물을 유효성분으로 포함하는 황반 변성 치료용 약학적 조성물
KR101359759B1 (ko) 펜톡시필린을 유효성분으로 함유하는 타우 단백질 과인산화 억제제
KR101729078B1 (ko) 엔아미드류 화합물을 유효성분으로 함유하는 항비만 조성물
KR20130065899A (ko) 티오아데노신 유도체 및 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 퇴행성 뇌질환 치료 및 예방용 조성물
KR101968299B1 (ko) Lappaol A를 유효성분으로 하는 항알레르기 조성물

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210405

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221011